Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
已完结
100
由 医休 发布于 2026/6/17 9:18:37
DOI:10.1200/JCO.19.00210
作者：X. Sheng,?Xieqiao Yan,?Z. Chi,?L. Si,?C. Cui,?B. Tang,?Si-ming Li,?L. Mao,?B. Lian,?Xuan Wang,?X. Bai,?Li Zhou,?Y. Kong,?J. Dai,?Kai Wang,?Xiongwen Tang,?Huaning Zhou,?Hai Wu,?H. Feng,?S. Yao,?K. Flah
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1200/JCO.19.00210
作者：X. Sheng,?Xieqiao Yan,?Z. Chi,?L. Si,?C. Cui,?B. Tang,?Si-ming Li,?L. Mao,?B. Lian,?Xuan Wang,?X. Bai,?Li Zhou,?Y. Kong,?J. Dai,?Kai Wang,?Xiongwen Tang,?Huaning Zhou,?Hai Wu,?H. Feng,?S. Yao,?K. Flah
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1200/JCO.19.00210
American Society of Clinical Oncology (ASCO)
其它数据库
Nature
京公网安备 11010802042870号
